阿糖胞苷
阿糖胞苷用途
Cytarabine是一种用于治疗急性髓性白血病的化疗药物,抑制DNA 合成的IC50为16 nM。
阿糖胞苷名称
[ CAS 号 ]:
147-94-4
[ 中文名 ]:
阿糖胞苷
[ 英文名 ]:
Cytarabine
[中文别名 ]:
- 阿糖胞嘧啶
- 胞嘧啶-1-Β-D(+)-阿拉伯呋喃酐
- 胞嘧啶β-D-呋喃阿拉伯糖苷
- 阿拉伯糖胞嘧啶
- 阿哌沙班
- 海綿胞嘧啶
- 胞嘧啶-β-D-呋喃阿拉伯糖苷
- 阿糖呋喃胞嘧啶
- 胞嘧啶阿拉伯糖苷
- (β-D-阿拉伯呋喃糖基)胞嘧啶
[英文别名 ]:
- MFCD00066487
- Cytosine β-D-Arabinofuranoside
- Cytarabine
- Arabinosylcytosine
- 4-Amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone
- Arabinocytidine
- (β-D-Arabinofuranosyl)cytosine
- EINECS 205-705-9
- Arabinofuranosylcytosine
- (β-D-Arabinofuranosyl)cytosine
阿糖胞苷生物活性
[ 描述 ]:
Cytarabine是一种用于治疗急性髓性白血病的化疗药物,抑制DNA 合成的IC50为16 nM。
[ 相关类别 ]:
[ 靶点 ]
IC50: 16 nM (DNA synthesis)
[体外研究]
阿糖胞苷被磷酸化为三磷酸盐形式(Ara-CTP),涉及脱氧胞苷激酶(dCK),其与dCTP竞争结合到DNA中,然后通过抑制DNA和RNA聚合酶的功能阻断DNA合成。与其他急性髓性白血病(AML)细胞相比,阿糖胞苷对野生型CCRF-CEM细胞显示出更高的生长抑制活性,IC50为16 nM [1]。阿糖胞苷明显诱导大鼠交感神经元凋亡10μM,其中100μM显示最高毒性,并在84小时内杀死超过80％的神经元,包括线粒体细胞色素c的释放和caspase-3的激活,以及通过p53敲低可以减弱毒性,并通过bax缺失延迟[2]。
[体内研究]
阿糖胞苷(250 mg/kg)也会导致胎盘生长迟缓,并增加胎盘迷路细胞凋亡,在孕期Slc：Wistar大鼠的胎盘迷路区,从治疗后3小时开始增加,并在恢复到对照水平前6小时达到峰值。 48小时,p53蛋白显着增强,p53转录靶基因如p21,cyclinG1和fas和caspase-3活性[3]。阿糖胞苷对急性白血病非常有效,导致阿糖胞苷的G1/S阻滞和同步化,并以弱剂量相关的方式增加白血病布朗挪威大鼠的存活时间,表明使用更高剂量的阿糖胞苷无助于它对人体的抗白血病作用[4]。
[激酶实验]
在无水乙醇中制备阿糖胞苷的储备溶液，并制备阿糖胞苷的连续稀释液。将CCRF-CEM细胞悬浮于补充有10％FBS，0.1％庆大霉素和1％丙酮酸钠的RPMI培养基中。将细胞悬浮在它们各自的培养基中，得到10mL体积的细胞悬浮液，最终密度为3-6×10 4个细胞/ mL。将适量的阿糖胞苷溶液转移至细胞悬浮液中，并继续培养72小时。将细胞离心并重新悬浮于不含阿糖胞苷的新培养基中，并测定最终细胞计数。通过细胞计数与阿糖胞苷浓度的S形曲线拟合分析数据，结果表示为IC 50（抑制细胞生长的阿糖胞苷浓度至对照值的50％）。
[动物实验]
怀孕大鼠在妊娠第13天（GD13）腹膜内（ip）注射250mg / kg阿糖胞苷。在本实验条件下，围产儿胎儿先天畸形和生长迟缓检出率较高，但胎儿死亡率并未明显增加。在处理后1,3,6,9,12,24和48小时，在乙醚麻醉下通过心脏穿刺杀死6个水坝，并收集胎盘。作为对照，在GD13上腹膜内注射6只怀孕的大鼠，并在与阿糖胞苷处理组相同的时间点处死。在每个时间点获得的六个母坝中，三个用于组织病理学分析，三个用于逆转录 - 聚合酶链反应（RT-PCR）分析。
[参考文献]
[相关活性小分子]
阿扎胞苷
|
5-溴-2'-脱氧尿苷
|
盐酸呋咯地辛
|
5-氟-2'-脱氧脲核苷
|
雷替曲塞
|
曲氟尿苷
|
阿糖腺苷
|
盐酸Tipiracil
|
克罗拉滨
|
去氧氟尿苷
|
奈拉滨
|
8-氮鸟嘌呤
|
氟环戊烯基胞嘧啶
|
替加氟
|
LY2334737
阿糖胞苷物理化学性质
[ 密度 ]:
1.9±0.1 g/cm3
[ 沸点 ]:
529.7±60.0 °C at 760 mmHg
[ 熔点 ]:
214 °C
[ 分子式 ]:
C9H13N3O5
[ 分子量 ]:
243.217
[ 闪点 ]:
274.1±32.9 °C
[ 精确质量 ]:
243.085526
[ PSA ]:
130.83000
[ LogP ]:
-1.78
[ 外观性状 ]:
白色细小针状结晶或结晶性粉末。溶于水，部分溶于甲醇，几乎不溶于乙醚，本品以D-阿拉伯糖或5′-胞嘧啶核苷酸为原料制得。常用其盐酸盐。熔点：214℃ 为抗肿瘤药，是一种抗嘧啶类抗代谢物，可抑制DNA聚合酶，干扰核苷酸参入DNA，并抑制核苷酸还原酶，阻断胞嘧啶核苷酸还原成脱氧胞嘧啶核苷酸，但对RNA和蛋白质的合成无显著作用。
[ 蒸汽压 ]:
0.0±3.2 mmHg at 25°C
[ 折射率 ]:
1.756
[ 储存条件 ]:
2-8°C
[ 水溶解性 ]:
H2O: 50 mg/mL, clear, colorless
阿糖胞苷MSDS
阿糖胞苷毒性和生态
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- HA5425000
- CHEMICAL NAME :
- Cytosine, 1-beta-D-arabinofuranosyl-
- CAS REGISTRY NUMBER :
- 147-94-4
- LAST UPDATED :
- 199806
- DATA ITEMS CITED :
- 122
- MOLECULAR FORMULA :
- C9-H13-N3-O5
- MOLECULAR WEIGHT :
- 243.25
- WISWESSER LINE NOTATION :
- T6NVNJ DZ A- BT5OTJ CQ DQ E1Q
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- Standard Draize test
- ROUTE OF EXPOSURE :
- Administration onto the skin
- SPECIES OBSERVED :
- Human
- TYPE OF TEST :
- Standard Draize test
- ROUTE OF EXPOSURE :
- Administration into the eye
- SPECIES OBSERVED :
- Human
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 60 mg/kg/90W-I
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Ear) - change in acuity Behavioral - ataxia Blood - changes in spleen
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 6480 ug/kg/12D-I
- TOXIC EFFECTS :
- Blood - other changes
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human - child
- DOSE/DURATION :
- 33200 ug/kg/240D-I
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Nutritional and Gross Metabolic - body temperature increase
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human
- DOSE/DURATION :
- 17241 mg/kg/6D-I
- TOXIC EFFECTS :
- Skin and Appendages - dermatitis, allergic (after systemic exposure)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 720 mg/kg/3D-I
- TOXIC EFFECTS :
- Brain and Coverings - other degenerative changes
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 649 mg/kg/4D-I
- TOXIC EFFECTS :
- Peripheral Nerve and Sensation - fasciculations
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 1536 mg/kg/43W-I
- TOXIC EFFECTS :
- Peripheral Nerve and Sensation - fasciculations Behavioral - ataxia
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 23500 ug/kg/7D-C
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Eye) - visual field changes Sense Organs and Special Senses (Eye) - lacrimation Sense Organs and Special Senses (Eye) - conjunctive irritation
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >5 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >5 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >5 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >5 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 3150 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 3779 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >10 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >7 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Administration onto the skin
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 875 mg/kg/5W-I
- TOXIC EFFECTS :
- Endocrine - changes in spleen weight Blood - changes in erythrocyte (RBC) count Blood - changes in leukocyte (WBC) count
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 300 mg/kg/5D-I
- TOXIC EFFECTS :
- Blood - changes in bone marrow (not otherwise specified) Blood - changes in leukocyte (WBC) count Nutritional and Gross Metabolic - weight loss or decreased weight gain
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 280 mg/kg/7D-I
- TOXIC EFFECTS :
- Gastrointestinal - other changes Blood - changes in erythrocyte (RBC) count Nutritional and Gross Metabolic - weight loss or decreased weight gain
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Primate - monkey
- DOSE/DURATION :
- 280 mg/kg/7D-I
- TOXIC EFFECTS :
- Behavioral - food intake (animal) Gastrointestinal - hypermotility, diarrhea Blood - changes in erythrocyte (RBC) count
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 2500 mg/kg/7W-I
- TOXIC EFFECTS :
- Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - lymphoma, including Hodgkin's disease Skin and Appendages - tumors
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 4836 mg/kg/26W-I
- TOXIC EFFECTS :
- Tumorigenic - equivocal tumorigenic agent by RTECS criteria Lungs, Thorax, or Respiration - tumors Blood - lymphoma, including Hodgkin's disease
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 100 mg/kg
- SEX/DURATION :
- female 11 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - other effects to embryo
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 20 mg/kg
- SEX/DURATION :
- female 11 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 50 mg/kg
- SEX/DURATION :
- female 12 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 30 mg/kg
- SEX/DURATION :
- female 12 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 7500 ug/kg
- SEX/DURATION :
- female 10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 75 mg/kg
- SEX/DURATION :
- female 18-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 90 mg/kg
- SEX/DURATION :
- female 9-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 360 mg/kg
- SEX/DURATION :
- female 9-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 180 mg/kg
- SEX/DURATION :
- female 9-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetal death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Unreported
- DOSE :
- 50 mg/kg
- SEX/DURATION :
- female 12 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 5 mg/kg
- SEX/DURATION :
- female 10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 60 mg/kg
- SEX/DURATION :
- female 13-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 5 mg/kg
- SEX/DURATION :
- female 11 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 25 mg/kg
- SEX/DURATION :
- female 10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 33 mg/kg
- SEX/DURATION :
- male 1 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 60 mg/kg
- SEX/DURATION :
- female 13-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - Central Nervous System
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 50 mg/kg
- SEX/DURATION :
- female 12 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 80 mg/kg
- SEX/DURATION :
- female 6-15 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 45 mg/kg
- SEX/DURATION :
- female 7-12 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Effects on Newborn - live birth index (measured after birth)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 18 mg/kg
- SEX/DURATION :
- female 7-12 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 9 mg/kg
- SEX/DURATION :
- female 7-12 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Parenteral
- DOSE :
- 60 mg/kg
- SEX/DURATION :
- female 13-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
- TYPE OF TEST :
- Specific locus test
- TYPE OF TEST :
- Specific locus test
- TYPE OF TEST :
- Cytogenetic analysis
- TYPE OF TEST :
- Micronucleus test
- TYPE OF TEST :
- Micronucleus test
- TYPE OF TEST :
- Unscheduled DNA synthesis
- TYPE OF TEST :
- DNA inhibition
- TYPE OF TEST :
- DNA inhibition
- TYPE OF TEST :
- DNA inhibition
- TYPE OF TEST :
- Cytogenetic analysis
- TYPE OF TEST :
- Cytogenetic analysis
- TYPE OF TEST :
- Sister chromatid exchange
- TYPE OF TEST :
- Dominant lethal test
- TYPE OF TEST :
- Sperm Morphology
- TYPE OF TEST :
- DNA inhibition
MUTATION DATA
- TYPE OF TEST :
- Cytogenetic analysis
- TEST SYSTEM :
- Mammal - species unspecified Fibroblast
- DOSE/DURATION :
- 15 umol/L
- REFERENCE :
- MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 178,73,1987 *** REVIEWS *** TOXICOLOGY REVIEW 32XPAD "Teratology," Berry, C.L., and D.E. Poswillo, eds., New York, Springer, 1975 Volume(issue)/page/year: -,49,1975 TOXICOLOGY REVIEW ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI. Volume(issue)/page/year: 5,447,1965 TOXICOLOGY REVIEW CRTXB2 CRC Critical Reviews in Toxicology. (CRC Press, Inc., 2000 Corporate Blvd., NW, Boca Raton, FL 33431) V.1- 1971- Volume(issue)/page/year: 2,159,1973 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3689 No. of Facilities: 450 (estimated) No. of Industries: 1 No. of Occupations: 7 No. of Employees: 18673 (estimated) No. of Female Employees: 12859 (estimated)
阿糖胞苷安全信息
[ 符号 ]:
GHS07, GHS08
[ 信号词 ]:
Warning
[ 危害声明 ]:
H317-H361
[ 警示性声明 ]:
P280
[ 个人防护装备 ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
[ 危害码 (欧洲) ]:
Xn:Harmful
[ 风险声明 (欧洲) ]:
R43;R63
[ 安全声明 (欧洲) ]:
S36/37
[ 危险品运输编码 ]:
NONH for all modes of transport
[ WGK德国 ]:
3
[ RTECS号 ]:
HA5425000
[ 海关编码 ]:
2934999090
阿糖胞苷合成路线
阿糖胞苷上下游产品
阿糖胞苷上游产品
阿糖胞苷下游产品
阿糖胞苷制备
由5-胞嘧啶核苷酸经水解后，得到胞嘧啶核苷，经氯化、环氧化和氨水中水解，最后成盐制得。
阿糖胞苷海关
[ 海关编码 ]: 2934999090
[ 中文概述 ]:
2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
[ 申报要素 ]: 品名, 成分含量, 用途
[ Summary ]:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
阿糖胞苷文献
Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells.
Br. J. Cancer 111(5) , 874-82, (2014)
Standard therapy for acute promyelocytic leukaemia (APL) includes retinoic acid (all-trans retinoic acid (ATRA)), which promotes differentiation of promyelocytic blasts. Although co-administration of ...
African swine fever virus ORF P1192R codes for a functional type II DNA topoisomerase.Virology 474 , 82-93, (2014)
Topoisomerases modulate the topological state of DNA during processes, such as replication and transcription, that cause overwinding and/or underwinding of the DNA. African swine fever virus (ASFV) is...
PMP22 is critical for actin-mediated cellular functions and for establishing lipid rafts.J. Neurosci. 34(48) , 16140-52, (2014)
Haploinsufficiency of peripheral myelin protein 22 (PMP22) causes hereditary neuropathy with liability to pressure palsies, a peripheral nerve lesion induced by minimal trauma or compression. As PMP22...
相关药品：
推荐生产厂家/供应商：
公司名：襄阳美均机械技术检测有限公司
区域：襄樊市樊城区
价格：
￥40.0/1g
￥120.0/5g
￥415.0/25g
联系人：石余兵
产品详情：阿糖胞苷
公司名：上海吉至生化科技有限公司
区域：上海市奉贤区
价格：
￥558.0/25g
￥158.0/5g
联系人：刘佳
产品详情：阿糖胞苷
公司名：上海源溪生物科技有限公司
区域：上海市浦东新区
价格：
￥需询单/1g
联系人：赖经理
公司名：上海脉铂医药科技有限公司
区域：上海市嘉定区
价格：
￥489.0/200mg
￥1489.0/1g
￥539.0/1g
￥需询单/1g
联系人：李先生
产品详情：Cytarabine
公司名：上海阿拉丁生化科技股份有限公司
区域：上海市浦东新区
价格：
￥29.9/1g
￥362.9/25g
￥91.9/5g
￥176.9/1ml
联系人：阿拉丁李高志
产品详情：阿糖胞苷
查看所有供应商请点击：
阿糖胞苷相关知识
2022-04-29 19:36:01
一、小剂量维持治疗时疗程偏短 本品口服吸收少，静脉注射后迅速消除，半衰期为2-3h，且24h内有70%-90%从尿液中排除，临床上在静脉给药时尤其要注意，除中、大剂量的攻击性治疗外，说明书注明采用小剂量方案时，1个疗程至少需连续每天给药5天以上，以覆盖至少1个完整的细胞繁殖周期（骨髓造血干细胞一...
相关化合物
【阿糖胞苷】化源网提供阿糖胞苷CAS号147-94-4，阿糖胞苷MSDS及其说明、性质、英文名、生产厂家、作用/用途、分子量、密度、沸点、熔点、结构式等。CAS号查询阿糖胞苷上化源网，专业又轻松。>>电脑版：阿糖胞苷
标题：阿糖胞苷_MSDS_用途_密度_阿糖胞苷CAS号【147-94-4】_化源网 地址：https://www.chemsrc.com/amp/cas/147-94-4_123927.html